These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29475164)

  • 1. Thiazolidinediones as antidiabetic agents: A critical review.
    Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
    Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.
    Yasmin S; Jayaprakash V
    Eur J Med Chem; 2017 Jan; 126():879-893. PubMed ID: 27988463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
    Ahsan W
    Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
    Vázquez M; Silvestre JS; Prous JR
    Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake.
    Christensen KB; Minet A; Svenstrup H; Grevsen K; Zhang H; Schrader E; Rimbach G; Wein S; Wolffram S; Kristiansen K; Christensen LP
    Phytother Res; 2009 Sep; 23(9):1316-25. PubMed ID: 19172665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational drug design and PPAR agonists.
    Perfetti R; D'Amico E
    Curr Diab Rep; 2005 Oct; 5(5):340-5. PubMed ID: 16188168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR Agonists and Metabolic Syndrome: An Established Role?
    Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M; Gutman W; Derlacz RA
    Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists.
    Yue TL
    Drugs Today (Barc); 2003 Dec; 39(12):949-60. PubMed ID: 14747840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
    Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
    Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
    Sugiyama Y; Murase K; Ikeda H
    Nihon Rinsho; 2000 Feb; 58(2):370-5. PubMed ID: 10707560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
    Lecka-Czernik B
    Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinedione safety.
    Kung J; Henry RR
    Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones.
    Kurogi Y
    Drug Des Discov; 1999 Aug; 16(2):109-18. PubMed ID: 10533807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.